Eisai appoints chief clinical officer

pharmafile | April 12, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing |  Eisai 

Eisai has announced the immediate appointment of Lynn Kramer to the newly created position of chief clinical officer of Eisai Product Creation Systems.

In this role, Dr Kramer will be responsible for the approval of protocol designs of pivotal studies to achieve timely regulatory approval of competitive labels for new products, indications and life-cycle extensions.

This includes the selection of study regions and clinical sites. He also will provide oversight of the design of Proof of Concept (POC) Studies for each of Eisai’s Product Creation Units.

Advertisement

In addition to these new responsibilities, Kramer will continue to serve as president of the Neuroscience and General Medicine Product Creation Unit, a position he has held since July 2009. In this capacity, he is responsible for overseeing the full product creation cycle from discovery through regulatory approval of innovative projects in the neuroscience and general medicine areas. 

Kramer joined Eisai in 2007 as executive vice president of Global Clinical Research and was soon promoted to the additional role of chief clinical officer of Eisai Medical Research.

Related Content

Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)

Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical …

robina-weermeijer-ihfopazzjhm-unsplash_5

Eisai and EcoNaviSta enter dementia collaboration

Eisai and EcoNaviSta have announced that they have entered into a business alliance agreement, initiating …

robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a …

The Gateway to Local Adoption Series

Latest content